Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/41244
Title: Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis
Authors: Carr, Susan J.
Wang, Xia
Olavarria, Veronica V.
Lavados, Pablo M.
Rodriguez, Jorge A.
Kim, Jong S.
Lee, Tsong-Hai
Lindley, Richard I.
Pontes-Neto, Octavio M.
Ricci, Stefano
Sato, Shoichiro
Sharma, Vijay K.
Woodward, Mark
Chalmers, John
Anderson, Craig S.
Robinson, Thompson G.
First Published: 24-Jul-2017
Publisher: American Heart Association
Citation: Stroke, 2017, 48 (9), pp. 2605-2609
Abstract: BACKGROUND AND PURPOSE: Renal dysfunction (RD) is associated with poor prognosis after stroke. We assessed the effects of RD on outcomes and interaction with low- versus standard-dose alteplase in a post hoc subgroup analysis of the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study). METHODS: A total of 3220 thrombolysis-eligible patients with acute ischemic stroke (mean age, 66.5 years; 37.8% women) were randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset. Six hundred and fifty-nine (19.8%) patients had moderate-to-severe RD (estimated glomerular filtration rate, <60 mL/min per 1.73 m(2)) at baseline. The impact of RD on death or disability (modified Rankin Scale scores, 2-6) at 90 days, and symptomatic intracerebral hemorrhage, was assessed in logistic regression models. RESULTS: Compared with patients with normal renal function (>90 mL/min per 1.73 m(2)), those with severe RD (<30 mL/min per 1.73 m(2)) had increased mortality (adjusted odds ratio, 2.07; 95% confidence interval, 0.89-4.82; P=0.04 for trend); every 10 mL/min per 1.73 m(2) lower estimated glomerular filtration rate was associated with an adjusted 9% increased odds of death from thrombolysis-treated acute ischemic stroke. There was no significant association with modified Rankin Scale scores 2 to 6 (adjusted odds ratio, 1.03; 95% confidence interval, 0.62-1.70; P=0.81 for trend), modified Rankin Scale 3 to 6 (adjusted odds ratio, 1.20; 95% confidence interval, 0.72-2.01; P=0.44 for trend), or symptomatic intracerebral hemorrhage, or any heterogeneity in comparative treatment effects between low-dose and standard-dose alteplase by RD grades. CONCLUSIONS: RD is associated with increased mortality but not disability or symptomatic intracerebral hemorrhage in thrombolysis-eligible and treated acute ischemic stroke patients. Uncertainty persists as to whether low-dose alteplase confers benefits over standard-dose alteplase in acute ischemic stroke patients with RD. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01422616.
DOI Link: 10.1161/STROKEAHA.117.017808
ISSN: 0039-2499
eISSN: 1524-4628
Links: http://stroke.ahajournals.org/content/48/9/2605
http://hdl.handle.net/2381/41244
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2017, American Heart Association. Deposited with reference to the publisher’s open access archiving policy.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
Stroke Thrombolysis in Renal Dysfunction 26 Jun 2017 CLEAN.pdfPost-review (final submitted author manuscript)144.12 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.